ATE414789T1 - Marker für lungentumore - Google Patents

Marker für lungentumore

Info

Publication number
ATE414789T1
ATE414789T1 AT02010275T AT02010275T ATE414789T1 AT E414789 T1 ATE414789 T1 AT E414789T1 AT 02010275 T AT02010275 T AT 02010275T AT 02010275 T AT02010275 T AT 02010275T AT E414789 T1 ATE414789 T1 AT E414789T1
Authority
AT
Austria
Prior art keywords
tumors
nucleic acids
marker
lung cancer
relates
Prior art date
Application number
AT02010275T
Other languages
English (en)
Inventor
Johannes Coy
Rainer Hipfel
Birgit Wasser
Original Assignee
Mtm Lab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mtm Lab Ag filed Critical Mtm Lab Ag
Application granted granted Critical
Publication of ATE414789T1 publication Critical patent/ATE414789T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
AT02010275T 2002-05-21 2002-05-21 Marker für lungentumore ATE414789T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20020010275 EP1365032B1 (de) 2002-05-21 2002-05-21 Marker für Lungentumore

Publications (1)

Publication Number Publication Date
ATE414789T1 true ATE414789T1 (de) 2008-12-15

Family

ID=29286116

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02010275T ATE414789T1 (de) 2002-05-21 2002-05-21 Marker für lungentumore
AT03735709T ATE389033T1 (de) 2002-05-21 2003-05-16 Marker fur lungentumoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03735709T ATE389033T1 (de) 2002-05-21 2003-05-16 Marker fur lungentumoren

Country Status (9)

Country Link
US (2) US7355025B2 (de)
EP (2) EP1365032B1 (de)
JP (2) JP4520848B2 (de)
AT (2) ATE414789T1 (de)
AU (1) AU2003238077A1 (de)
CA (1) CA2486583C (de)
DE (2) DE60229920D1 (de)
ES (2) ES2316501T3 (de)
WO (1) WO2003097871A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026896A1 (en) 2016-08-02 2018-02-08 Georgetown University Methods of identifying novel proteins and antigens in cancer cells
MX2022001468A (es) 2019-08-09 2022-07-19 Nutcracker Therapeutics Inc Metodos y aparatos de fabricación para remover material de una composición terapeutica.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US6033847A (en) * 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
AU5485600A (en) * 1999-06-16 2001-01-02 Johns Hopkins University, The Characterization of the yeast transcriptome
US6806254B2 (en) * 2000-02-03 2004-10-19 Nuvelo, Inc. Methods and materials relating to alpha-2-macroglobulin-like polypeptides and polynucleotides
WO2001061055A2 (en) * 2000-02-17 2001-08-23 Diadexus, Inc. Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001077384A2 (de) * 2000-04-07 2001-10-18 Epigenomics Ag DETEKTION VON SNPs UND CYTOSIN-METHYLIERUNGEN
AU2001276919A1 (en) * 2000-07-13 2002-01-30 Genaissance Pharmaceuticals, Inc. Haplotypes of the mmp13 gene

Also Published As

Publication number Publication date
WO2003097871A2 (en) 2003-11-27
ES2316501T3 (es) 2009-04-16
ES2303595T3 (es) 2008-08-16
AU2003238077A8 (en) 2003-12-02
EP1506317A2 (de) 2005-02-16
JP2005525826A (ja) 2005-09-02
DE60229920D1 (de) 2009-01-02
WO2003097871A8 (en) 2004-03-04
DE60319693D1 (de) 2008-04-24
CA2486583C (en) 2013-09-24
CA2486583A1 (en) 2003-11-27
US7355025B2 (en) 2008-04-08
US20090098544A1 (en) 2009-04-16
US7883896B2 (en) 2011-02-08
EP1506317B1 (de) 2008-03-12
AU2003238077A1 (en) 2003-12-02
DE60319693T2 (de) 2009-03-05
EP1365032B1 (de) 2008-11-19
ATE389033T1 (de) 2008-03-15
WO2003097871A3 (en) 2004-02-05
EP1365032A1 (de) 2003-11-26
JP4520848B2 (ja) 2010-08-11
JP2010017194A (ja) 2010-01-28
US20050176930A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
WO2005000098A3 (en) Detection methods for disorders of the lung
WO2005108415A8 (en) Membrane associated molecules
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
WO2008031839A3 (en) Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof
WO2007000320A3 (de) Verfahren zur diagnose von rheumatischen erkrankungen
WO2011027310A8 (en) Novel tumor markers
WO2005032495A8 (en) Gene expression profiles and methods of use
WO2011027308A8 (en) Novel tumor markers
DK1109021T3 (da) Snail, en ny tumoral progressionsmarkör og et targetprotein for nye antitumorale forbindelser
WO2010093872A3 (en) Molecular-based method of cancer diagnosis and prognosis
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
ATE534902T1 (de) Replikationsproteinn ciz1
ATE414789T1 (de) Marker für lungentumore
DE69834949T8 (de) Bestimmung der prädisposition für obstruktive lungenerkrankung basierend auf genpolymorphismen der humanen luftweg-trypsin-protease
WO2011027311A3 (en) Novel tumor markers
WO2011073905A8 (en) Novel tumor markers
WO2011073901A8 (en) Novel tumor markers
WO2002040673A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2005017102A3 (en) Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
ES2189560B1 (es) Dna polimerasa k, nuevo marcador tumoral.
WO2007001399A3 (en) Compositions, splice variants and methods relating to cancer specific genes and proteins
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
Feng et al. LncRNA FGD5-AS1 drives the malignant development of gastric cancer by negatively interacting with FZD3
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2003020899A3 (en) Compositions and methods relating to lung specific genes and proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties